Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
36 studies found for:    " February 05, 2012":" March 06, 2012"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
Rank Status Study
21 Completed A Study to Compare Three Different Formulations of Tenofovir 1% Gel When Administered Rectally
Condition: HIV Prevention
Interventions: Drug: Rectal formulation (RF) of tenofovir 1% gel;   Drug: Vaginal formulations (original VF and reduced vaginal glycerin formulation RGVF) of tenofovir 1% gel;   Drug: Universal HEC Placebo Gel Formulation
22 Recruiting Dolutegravir Expanded Access Study
Condition: Infection, Human Immunodeficiency Virus
Intervention: Drug: Dolutegravir
23 Unknown  Safety of Reduced Dose Zidovudine (AZT) Compared With Standard Dose AZT in Antiretroviral-naïve HIV-infected Patients
Conditions: HIV;   Zidovudine Adverse Reaction
Intervention: Drug: Zidovudine
24 Completed Phase I/IIa Dose-escalation Clinical Study of VAC-3S
Condition: HIV-1 Infection
Interventions: Biological: VAC-3S;   Biological: Placebo
25 Completed Early Access to Low-dose Ritonavir (TMC114/r) and Other Antiretrovirals (ARVs) for Treatment-naive or Early Treatment Experienced in HIV-1 Patients
Condition: HIV-1
Intervention: Drug: TMC114/ritonavir
26 Unknown  Observational Study of Effect of Radiation Therapy to Immuno Status in HIV-cancer Patients
Conditions: To Study Immunostatus of HIV-cancer Patients Who Recived RT Befor RT and Last Week of RT;   To Study HIV Viral Load of HIV-cancer Patients Who Recived RT Befor RT and Last Week of RT
Interventions: Radiation: Radiation therapy;   Other: Venepuncture
27 Completed
Has Results
Sevelamer for Reducing Endotoxemia and Immune Activation
Condition: HIV-1 Infection
Interventions: Drug: Sevelamer carbonate;   Device: Sevelamer carbonate
28 Completed Effects of Losartan and Antiretroviral Regimen Containing Raltegravir in Fibrosis Inflammation Mediators, Cardiovascular Risk and Neurocognitive Disorders in HIV Infected Patients Previously Effectively Treated
Condition: HIV-1 Infection
Interventions: Drug: EFV/FTC/TDF + Losartan;   Drug: EFV/FTC/TDF;   Drug: FTC/TDF + MK-0518;   Drug: FTC/TDF+MK-0518+Losartan
29 Active, not recruiting Gender-Specific Combination HIV Prevention for Youth in High Burden Settings (MP3-Youth)
Conditions: HIV;   Adolescent Behavior;   Gender
Interventions: Other: Male-Specific Intervention Package;   Other: Female-Specific Intervention Package;   Drug: Pre-Exposure Prophylaxis (Females);   Behavioral: Cash Transfer Cohort (Females)
30 Completed
Has Results
Intervention to Retain HIV-positive Patients in Medical Care
Condition: Primary Care Appointment Keeping
Interventions: Behavioral: Enhanced contact plus behavioral skills;   Behavioral: Enhanced contact only;   Behavioral: Standard of Care
31 Completed Methadone Maintenance and HIV Prevention: A Window of Opportunity in China
Conditions: Capacity Building;   Drug Use;   HIV/AIDS
Intervention: Behavioral: MMT CARE
32 Unknown  Improving Blood Safety and HIV Testing in Brazil
Conditions: HIV;   Herpes Simplex 2;   Hepatitis C;   Hepatitis B;   Chagas Disease
Interventions: Behavioral: HIV Counseling and Testing;   Behavioral: Blood Donation
33 Unknown  A Clinical Outcomes Study to Measure Reduction in Pain and Numbness During Administration of an Amino Acid Formulation in Subjects Diagnosed With Peripheral Neuropathy
Conditions: Diabetic Neuropathy;   Chemotherapy Induced Neuropathy;   HIV Neuropathy;   Trauma Induced Neuropathy
Intervention: Drug: Neuron012703 (Medical Food)
34 Unknown  A Study of Co-infections of HIV-1 and Schistosoma Mansoni and Its Impact on Praziquantel Treatment Outcomes
Conditions: Anemia;   Intestinal Helminthiasis;   Intestinal Schistosomiasis;   Human Immunodeficiency Virus I Infection;   Hematologic Diseases;   Opportunistic Infections
Intervention: Drug: Praziquantel and Albendazole
35 Completed Project N-Liten- HIV Prevention for African American Women
Condition: Sexually Transmitted Diseases
Interventions: Behavioral: Horizons+General Health Promotion (GHP);   Behavioral: Horizons+Motivational Enhancement Therapy (GMET)
36 Completed Operational Research for Cryptococcal Antigen Screening
Conditions: Cryptococcal Meningitis;   Cryptococcus Neoformans;   Cryptococcosis
Intervention: Drug: Fluconazole

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-36) Next Page   
Study has passed its completion date and status has not been verified in more than two years.